ResMed enhances incentive plans, board structure changes after annual meeting

ResMed Inc. reported significant outcomes from its November 19, 2025, annual meeting, including stockholder approval for amendments to its 2009 Incentive Award Plan and 2018 Employee Stock Purchase Plan. The 2009 Incentive Award Plan now reserves an additional 2.4m shares of common stock, eliminates its fixed term, and authorizes incentive stock options. Concurrently, the 2018 Employee Stock Purchase Plan has increased its reserved common stock by 3m shares and removed its fixed term.

In board-related news, Richard Sulpizio did not seek re-election, creating a vacancy and prompting the board to reduce the director count from twelve to eleven. All eleven director nominees were elected to serve until the 2026 annual meeting. Additionally, KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending June 30, 2026.

Separate filings detail stock transactions by key personnel. Peter C. Farrell, director and chairman emeritus, exercised options for 11,442 common stock shares and disposed of 7,314 shares for tax withholding on November 14, 2025. Michael Rider and Harjit Gill also reported dispositions for tax withholding on November 11, 2025, of 162.953 and 38.209 shares respectively, both at $250.1 per share.